Guidelines for the diagnosis, prevention and treatment of osteoporosis, 2012;Guías 2012 para el diagnóstico, la prevención y el tratamiento de la osteoporosis

Medicina (Argentina)

Volumn 73, Issue 1, 2013, Pages 55-74

  Schurman, León ^a   Bagur, Alicia ^b   Claus Hermberg, Haraldo ^c   Messina, Osvaldo D ^d   Negri, Armando L ^e   Sánchez, Ariel ^f   González, Claudio ^g   Diehl, María ^h   Rey, Paula ^e   Gamba, Julieta ^d   Chiarpenello, Javier ⁱ   Moggia, María Susana ^j   Mastaglia, Silvina ^k  

^a UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^b Centro de Osteopatias Medicas   (Argentina)

^c HOSPITAL ALEMÁN   (Argentina)

^d HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^e UNIVERSIDAD DEL SALVADOR   (Argentina)

^f Expresidente de la Asociación Argentina de Osteología y Metabolismo Mineral   (Argentina)

^g CEMIC   (Argentina)

^h HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

ⁱ UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^j HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^k Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

more..

Author keywords

Control; Osteoporosis guidelines; Osteoporosis prevention ; Osteoporosis treatment

Indexed keywords

ARTICLE; HUMAN; OSTEOPOROSIS; PRACTICE GUIDELINE;

ARGENTINA; BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RISK FACTORS; VITAMIN D;

EID: 84877885884     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (153)

1. Schurman L, Bagur A, Claus-Hermberg H, Messina OD, Negri A, Sánchez A. Guías Argentinas para Diagnóstico, Prevención y Tratamiento de la Osteoporosis 2007. Actual Osteol 2007; 3: 117-36; y Rev Arg Osteol 2007; 6: 27-42 (doble publicación).
2. Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical Practice Guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Ass J 2002; 167: S1-S34.
3. Salica D, Buceta A, Palacios S, Sánchez A, et al. Consenso Iberoamericano de Osteoporosis SIBOMM 2009. Osteoporosis: Prevención, Diagnóstico y Tratamiento. Rev Arg Osteol 2010; 9: 4-44.
4. Spivacow FR, Sánchez A. Epidemiology, costs, and burden of osteoporosis in Argentina, 2009. Arch Osteoporos 2010; 5: 1-6.
5. Harvey N, Earl S, Cooper C. The epidemiology of osteoporotic fractures. En: Favus MJ, founding editor, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th edition. Washington DC: American Society for Bone and Mineral Research, 2006, p 244-8.
6. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22: 465-75.
7. Cipitria JA, Sosa MM, Pezzotto SM, Puche RC, Bocanera R. Outcome of hip fractures among elderly subjects. Medicina (B Aires) 1997; 57: 530-4.
8. Claus-Hermberg H, Lozano Bullrich MP, Ilera V, Malter Terrada J, Pozzo MJ. Incidencia de fractura de cadera en mujeres afiliadas al plan médico del Hospital Alemán, Buenos Aires. Actual Osteol 2008; 4: 57-62.
9. Beratarrechea A, Diehl M, Saimovici J, Pace N, Trossero A, Plantalech L. Mortalidad a largo plazo y factores predictores en pacientes con fractura de cadera. Actual Osteol 2011; 7: 9-18.
10. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301: 513-21.
11. CELADE. América Latina: Población por años calendario y edades simples 1995-2005. Boletín Demográfico N° 66. CEPAL; Santiago (Chile), 2000.
12. Siris E, Chen Y-T, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004; 164: 1108-12.
13. Freitas SS, Barett-Connor E, Ensrud KE, et al; Osteoporotic Fractures in Men (MrOS) Research Group. Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int 2008; 19: 615-23.
14. Mosquera MT, Maurel DL, Pavón S, et al. Incidencia y factores de riesgo de la fractura de fémur proximal por osteoporosis. Rev Panam Salud Pública 1998; 3: 211-8.
15. Bagur A, Mautalen C, Rubin Z. Epidemiology of hip fractures in an urban population of central Argentina. Osteoporos Int 1994; 4: 332-5.
16. Bagur A, Rovai G, López Giovanelli J, et al. Incidencia de fracturas de cadera en Corrientes, Bariloche y Comodoro Rivadavia. Actual Osteol 2009; 5: 81-7.
17. Morosano M, Masoni A, Sánchez A. Incidence of hip fractures in the city of Rosario, Argentina. Osteoporos Int 2005; 16: 1339-44.
18. Somma LF, Rosso GZ, Trobo RI, Barreira JC, Messina OD. Epidemiología de fractura de cadera en Luján, Argentina (resumen). Osteology 2000; 3: 267.
19. Wittich A, Bagur A, Mautalen C, et al. Epidemiology of hip fracture in Tucuman, Argentina. Osteoporos Int 2010; 21: 1803-7.
20. Johnell O, Kanis J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-33.
21. Clark P, Cons-Molina F, Delezé M, et al. The prevalence of vertebral deformity in Latin-American countries: The Latin-American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 2009; 20: 275-82.
22. Body J-J, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010; 21: 1657-80.
23. Black DM. The role of clinical risk factors in the prediction of future risk. J Clin Densitom 1999; 2: 361-2.
24. Lindsay R. Osteoporosis. Estrogens and SERMS. En: Rosen CJ, editor principal. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th edition. Washington: American Society for Bone and Mineral Research, 2008, pp 234-6.
25. Nguyen ND, Pongchaiyakul C, Center JR, et al. Identification of high risk individuals for hip fracture: a 14-year prospective study. J Bone Miner Res 2005; 20: 1921-8.
26. Klotzbuecher C, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721-39.
27. Melton LJ 3rd, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999; 10: 214-21.
28. Kelley GA, Kelley KS, Tran ZV. Exercise and lumbar spine bone mineral density in postmenopausal women: a metaanalysis of individual patient data. J Gerontol A Biol Sci Med Sci 2002; 47: M599-M604.
29. Salica D. Osteoporosis inducida por tabaco. Rev Arg Osteol 2003; 2: 20-9.
30. Krall EA, Dawson-Hughes B. Smoking increases bone loss and decrease intestinal calcium absorption. J Bone Mineral Res 1999; 14: 215-20
31. Reid DM. Can high bone turnover markers identify osteopenic postmenopausal women at risk of future fracture? Nat Clin Pract Endocrinol Metab 2007; 3: 570-1.
32. Garnero P, Delmas PD. Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact 2004; 4: 50-63.
33. Messina OD, Somma LF, Tamborenea MI, Porrini AA, Man Z, Castelli G, et al. Guías para diagnóstico, prevención y tratamiento de la osteoporosis inducida por corticoides. Rev Arg Osteol 2006; 5(2): 24-31.
34. Crncevic Z, Raisz LG. Causes of secondary osteoporosis. J Clin Densitom 1998; 2: 79-92.
35. Tannirandorn P, Epstein S. Drug-induced bone loss. Osteoporos Int 2000; 11: 637-59.
36. Drezner MK. Treatment of anticonvulsivant drug induced bone disease. Epilepsy Behav 2004; 5(Suppl 2): 541-7.
37. Schwartz AV, Selimeyer DE, Vittinghoff E, et al. Thiazolidindiones use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-54.
38. Yang YX, Lewis JD, Epstein S, Metz DC. Long term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53.
39. González Macías J, Guañabens Gay N, Gómez Alonso C, et al. (Comité de Redacción en representación del Comité de Expertos de la SEIOMM para la elaboración de las Guías). Guías de práctica clínica en la osteoporosis postmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral. Rev Clin Esp 2008; 208: 1-24.
40. Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH. Enhanced prediction of fracture risk combining vertebral fracture status and bone mineral density. Osteoporos Int 2007; 18: 761-70.
41. Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137-48.
42. WHO Technical Report Series 843. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneve: WHO, 1994, p 26.
43. Lewiecki EM, Baim S, Binkley N, et al. Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. Southern Med J 2008; 101: 735-9.
44. Sedlinsky C, Medina L, Schurman L. Discordance within bone mineral density values in lumbar spine and femoral neck: is it valid to analyse a single area in order to make therapeutic decisions? (Abstract). Osteoporos Int 2004; 15(S1): 526.
45. Mansur JL, Cianciosi MC, Martella A. The difference of bone mineral density between both hips influences the WHO classification. J Bone Miner Res 2003; 18: S316.
46. Papaioannou A, Morin S, Cheung AM, et al., for the Scientific Advisory Council of Osteoporosis Canada. 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada: Summary. Can Med Ass J 2010; 182: 1864-73.
47. FRAX WHO Fracture Risk Assessment Tool. En: http://www.shef.ac.uk/FRAX/index.htm; consultado el 30/04/12.
48. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary referente intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96: 53-8.
49. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330: 1003.
50. Shea B, Wells G, Cranney A, et al. (Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group). Meta-analyses of therapies for postmenopausal osteoporosis, VII: meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002; 23: 552-9.
51. Jackson RD, LaCroix AZ, Gass M, et al. (Womeńs Health Initiative Investigators). Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669-83.
52. Schürch MA, Rizzoli R, Slosman D, Vadas L, Vergnaud P, Bonjour JP. Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 801-9.
53. Gardner MM, Phty M, Robertson MC, McGee R, Campbell AJ. Application of a falls prevention program for older people to primary health care practice. Prev Med 2002; 34: 546-53.
54. Robertson MC, Campbell AJ, Gardner MM, Devlin N. Preventing injuries in older people by preventing falls: a meta-analysis of individual-level data. J Am Geriatr Soc 2002; 50: 905-11.
55. Latham NK, Anderson CS, Reid IR. Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic review. J Am Geriatr Soc 2003; 1219-22.
56. Bischoff-Ferrari HA, Willet WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a metaanalysis of randomized controlled trials. JAMA 2005; 293: 2257-64.
57. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004; 291: 1999-2006.
58. Hollis BW. Circulating 25-hidroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135: 317-22.
59. Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hidroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204-10.
60. Jackson RD, LaCroix AZ, Grass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669-83.
61. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Positive association between 25-hidroxy vitamin D and bone mineral density: a population-based study of younger and older adults. Am J Med 2004; 116: 634-9.
62. Cooper L, Clifton-Bligh PB, Nery ML, et al. Vitamin D supplementation and bone mineral density in early posmenopausal women. Am J Clin Nutr 2003; 77: 1324-9.
63. Bischoff-Ferrari HA, Conzelmann M, Stähelin HB, et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? Osteoporos Int 2006; 17: 656-63.
64. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15: 1113-8.
65. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730-7.
66. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93: 677-81.
67. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89: 5387-91.
68. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005; 16: 155-62.
69. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005; 16: 737-42.
70. Sambrook PN, Cameron ID, Chen JS, et al. Influence of fall related factors and bone strength on fracture risk in the frail eldery. Osteoporos Int 2007; 18: 603-10.
71. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001; 12: 519-28.
72. Burger H, De Laet CE, Weel AE, et al. Added value of bone mineral density in hip fracture risk scores. Bone 1999; 25: 369-74.
73. Dargent-Molina P, Douchin MN, Cormier C, Meunier PJ, Bréart G; EPIDOS Study Group. Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: the EPIDOS prospective study. Osteoporosis Int 2002; 13: 593-9.
74. McGrother CW, Donaldson MM, Clayton D, et al. Evaluation of a hip fracture risk score for assessing elderly women: the Melton Osteoporotic Fracture (MOF) study. Osteoporos Int 2002; 13: 89-96.
75. Nishtala PS, Hilmer SN, Mc Lachlan AJ, et al. Impact of residential medication management reviews on drug burden index in aged care homes: a retrospective analysis. Drugs Aging 2009; 26: 677-86.
76. Nishtala PS, McLachlan AJ, Bell JS, Chen TF. Psychotropic prescribing in long term care facilities: impact of medication reviews and educational interventions. Am J Geriatr Psychiatry 2008; 16: 621-32.
77. Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008; 25: 1021-1031.
78. Rapp K, Lamb SE, Buchele G, et al. Prevention of falling in nursing homes: subgroup analyses of a randomized fall prevention trial. J Am Geriatr Soc 2008; 56: 1092-7.
79. Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ 2006; 332: 571-4.
80. Sawka AM, Boulos P, Beattie K, et al. Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 2005; 16: 1461-74.
81. Singh S, Sun H, Anis AH. Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents. J Rheumatol 2004; 31: 1607-13.
82. van Schoor NM, Asma G, Smit JH, Bouter LM, Lips P. The Amsterdam Hip Protector Study: compliance and determinants of compliance. Osteoporos Int 2003; 14: 353-9.
83. Warnke A, Meyer G, Bender R, Mühlhauser I. Predictors of adherence to the use of hip protectors in nursing home residents. J Am Geriatr Soc 2004; 52: 340-5.
84. Kiel DP, Magaziner J, Zimmerman S, et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA 2007; 298: 413-22.
85. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fractures in white women. N Engl J Med 1995; 332: 767-73.
86. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid- induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319-28.
87. Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a crosssectional outpatient study. Bone 2006; 39: 253-9.
88. Hansen KH, Wilson HA, Zapalowski C, Fink HA, Minisola S, Adler RA. Uncertainties in the prevention and treatment of glucocorticoid -induced osteoporosis. J Bone Miner Res 2011; 26: 1089-996.
89. Weinstein RS. Glucocorticoid-induced osteoporosis. En: Rosen C, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th ed. Washington, DC: ASBMR, 2008, p 267-72.
90. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48: 3224-9.
91. Tatsuno I, Sugiyama T, Suzuki S, et al. Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab 2009; 94: 1671-7.
92. Thompson JM, Modin GW, Arnaud CD, Lane NE. Not all postmenopausal women on chronic steroid and estrogen treatment are osteoporotic: predictors of bone mineral density. Calcif Tissue Int 1997; 61: 377-81.
93. Adler RA, Curtis JR, Saag K, Weinstein RS. Glucocorticoidinduced osteoporosis. En: Marcus R, Feldman D, Nelsen DA, Rosen CJ, eds. Osteoporosis, 3rd ed. San Diego: Elsevier-Academic Press, 2008, pp 1135-66.
94. Russcher H, Smit P, van den Akker ELT, et al. Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J Clin Endocrinol Metab 2005; 90: 5804-10.
95. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202-11.
96. Weinstein R. Glucocorticoid-induced bone disease. N Engl J Med 2011; 365: 62-70.
97. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-39.
98. Black DM, Delmas PD, Eastell R, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
99. Cumming SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
100. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate osteoporosis treatment study groups. JAMA 1997; 277: 1159-64.
101. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 year of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-38.
102. Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent fracture: The FLEX trial. J Bone Miner Res 2010; 25: 976-82.
103. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with post-menopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52.
104. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83-91.
105. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 74: 129-35.
106. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003; 32: 120-6.
107. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-40.
108. Delmas PD, Recker RR, Chesnutt III CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from BONE study. Osteoporos Int 2004; 15: 792-8.
109. Harris ST, Reginster JY, Harley C, et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the Valuation of IBandronate Efficacy (VIBE) database fracture study. Bone 2009; 44: 758-65
110. Black DM, Eastell R, Reid IR, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
111. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-809.
112. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progesterin on risk of fracture and bone mineral density. The Women's Health Initiative Randomized Trial. JAMA 2003; 290: 1729-38.
113. Jackson RD, Wactawski-Wende J, La Croix AZ, et al. Effects on conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy. Results from the Women's Health Initiative Randomized Trial. J Bone Miner Res 2006; 21: 817-28.
114. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone(1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
115. Hodsman AB, Bauer D, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703.
116. Meunier P, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
117. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-22.
118. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebocontrolled trial. Arthritis Rheum 2008; 58: 1687-95.
119. Reginster JY, Bruyère O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 2009; 45: 1059-64.
120. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 637-45.
121. Delmas PD, Genant HK, Crans GC, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522-32.
122. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis. A dose response study. BMJ 1992; 305: 556-61.
123. Cummings SR, San Martín J, McClung MR, et al. Denosumab for prevention of fracture in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65.
124. Boonen S, Haentjens P, Vandenput L, Vanderschueren D. Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. J Intern Med 2004; 255: 1-12.
125. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004; 7: 255-61.
126. Bruyère O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007; 92: 3076-81.
127. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164: 2024-30.
128. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647-57.
129. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005; 11: 545-60.
130. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243-53.
131. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006; 55: 103-15.
132. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008; 167: 1207-16.
133. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009; 113: 65-73.
134. Ries LAG. SEER cancer statistics review, 1975-2000. Bethesda: National Cancer Institute, 2003.
135. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289: 2673-2684.
136. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006; 113: 2425-2434.
137. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465-77.
138. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166: 772-780.
139. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573-1580.
140. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-3078.
141. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.
142. Peter CP, Handt LK, Smitch SM. Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 1998; 43: 1998-2002.
143. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophtalmol 1994; 118: 220-224.
144. Pazianas M, Abrahmsen BO. Safety of bisphosphonate. Bone 2011; 49: 103-10.
145. Recker RR, Lewiecki M, Miller PD, Reiffel J. Safety of bisphophonates in the treatment of osteoporosis. Amer J Med 2009; 122: S22-S32.
146. Shane E, Goldring S, Christakos S, et al. Osteonecrosis of the jaw: More research needed. J Bone Min Res 2006; 21: 1503-1505.
147. Reid I, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol 2009; 38: 5-9.
148. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Min Res 2010; 25: 1-28.
149. Ott SM. Long-term safety of bisphosphonate. J Clin Endocrinol Metab 2005; 90: 1897-9.
150. Pernicova I, Middleton ET, Aye M. Rash, strontium ranelate, and DRESS syndrome put into perspective. European Medicine Agency on the Alert. Osteoporos Int 2008; 10: 1811-2.
151. Cole Z, Denisson E, Cooper C. Update on the treatment of post-menopausal osteoporosis. Br Med Bull 2008; 86: 129-34.
152. Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 2011; 89: 91-104.
153. Lewiecki EM. Safety and tolerabilty of denosumab for the treatment of postmenopausal osteoporosis. Drug Health Patient Saf 2011; 3: 79-91.